- $293.68bn
- $320.18bn
- $60.12bn
- 97
- 43
- 63
- 75
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 12.51 | ||
PEG Ratio (f) | 0.61 | ||
EPS Growth (f) | 25.54% | ||
Dividend Yield (f) | 2.69% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 6.74 | ||
Price to Tang. Book | 54.02 | ||
Price to Free Cashflow | 22.34 | ||
Price to Sales | 4.7 | ||
EV to EBITDA | 16.37 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 17.86% | ||
Return on Equity | 33.39% | ||
Operating Margin | 24.75% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 39,121 | 41,518 | 48,704 | 59,283 | 60,115 | 64,108.63 | 68,336.04 | 7.29% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -6.22 | +21.23 | +42.86 | +8.79 | -21.6 | +40.78 | +21.05 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.
Directors
- Kenneth Frazier CHM (66)
- Robert Davis PRE (54)
- Caroline Litchfield CFO
- Dean Li CEX (58)
- Steven Mizell CHO (60)
- Jennifer Zachary EVP (43)
- Sanat Chattopadhyay EVP (61)
- Richard DeLuca EVP (58)
- Julie Gerberding EVP (65)
- Michael Klobuchar EVP
- Rita Karachun SVF (57)
- Michael Fleming SVP (62)
- Cristal Downing OTH
- Thomas Glocer LED (61)
- Mary Coe IND (54)
- Pamela Craig IND (64)
- Risa Lavizzo-Mourey IND (66)
- Stephen Mayo IND (59)
- Paul Rothman IND (63)
- Patricia Russo IND (69)
- Christine Seidman IND (68)
- Inge Thulin IND (67)
- Kathy Warden IND (49)
- Peter Wendell IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 28th, 1970
- Public Since
- January 1st, 1941
- No. of Shareholders
- 90,400
- No. of Employees
- 72,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 2,534,809,312
- Address
- 126 East Lincoln Avenue, RAHWAY, 07065
- Web
- https://www.merck.com/
- Phone
- +1 9087404000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for MRK
Upcoming Events for MRK
Merck & Co Inc at Bank of America Global Healthcare Conference
Q3 2024 Merck & Co Inc Earnings Release
Q3 2024 Merck & Co Inc Earnings Call
Q4 2024 Merck & Co Inc Earnings Release
Q4 2024 Merck & Co Inc Earnings Call
Similar to MRK
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 22:28 UTC, shares in Merck & Co are trading at $115.86. This share price information is delayed by 15 minutes.
Shares in Merck & Co last closed at $115.86 and the price had moved by +7.04% over the past 365 days. In terms of relative price strength the Merck & Co share price has underperformed the S&P500 Index by -15.33% over the past year.
The overall consensus recommendation for Merck & Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Merck & Co dividend yield is 2.62% based on the trailing twelve month period.
Last year, Merck & Co paid a total dividend of $3.04, and it currently has a trailing dividend yield of 2.62%.Looking ahead, shares in Merck & Co are due to go ex-dividend on 2024-09-16 and the next dividend pay date is 2024-10-07.
Merck & Co are due to go ex-dividend on 2024-09-16 and the next dividend pay date is 2024-10-07. The historic dividend yield on Merck & Co shares is currently 2.62%.
To buy shares in Merck & Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $115.86, shares in Merck & Co had a market capitalisation of $293.68bn.
Here are the trading details for Merck & Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: MRK
Based on an overall assessment of its quality, value and momentum Merck & Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Merck & Co is $139.94. That is 20.78% above the last closing price of $115.86.
Analysts covering Merck & Co currently have a consensus Earnings Per Share (EPS) forecast of $8.06 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Merck & Co. Over the past six months, its share price has underperformed the S&P500 Index by -12.73%.
As of the last closing price of $115.86, shares in Merck & Co were trading -4.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Merck & Co PE ratio based on its reported earnings over the past 12 months is 12.51. The shares last closed at $115.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Merck & Co's management team is headed by:
- Kenneth Frazier - CHM
- Robert Davis - PRE
- Caroline Litchfield - CFO
- Dean Li - CEX
- Steven Mizell - CHO
- Jennifer Zachary - EVP
- Sanat Chattopadhyay - EVP
- Richard DeLuca - EVP
- Julie Gerberding - EVP
- Michael Klobuchar - EVP
- Rita Karachun - SVF
- Michael Fleming - SVP
- Cristal Downing - OTH
- Thomas Glocer - LED
- Mary Coe - IND
- Pamela Craig - IND
- Risa Lavizzo-Mourey - IND
- Stephen Mayo - IND
- Paul Rothman - IND
- Patricia Russo - IND
- Christine Seidman - IND
- Inge Thulin - IND
- Kathy Warden - IND
- Peter Wendell - IND